4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Xencor, Inc. (XNCR) operates in the Biotechnology industry and is headquartered in Pasadena, United States with about 260 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, XNCR reported $126M in revenue and ($92M) in net income.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Interactive charts & full statements → Open the XNCR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $126M | $110M | $175M | $165M |
| Operating Income (EBIT) | ($178M) | ($178M) | ($132M) | ($82M) |
| Net Income | ($92M) | ($233M) | ($133M) | ($55M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $4M | $28M | $21M | $44M | $33M |
| Operating Income (EBIT) | ($78M) | ($54M) | ($48M) | ($33M) | ($43M) |
| Net Income | ($129M) | ($7M) | ($6M) | ($31M) | ($48M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $876M | $952M | $965M | $846M | — |
| Total Liabilities | $240M | $278M | $303M | $119M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XNCR viewer.
About TickerBase · Data methodology & sources